Navigation Links
Pfizer - Wyeth: Good Deal – Bad Deal?
Date:1/23/2009

If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies.

Oxford, UK (PRWEB) January 23, 2009 -- If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies. By 2012, the merged company will have lost $25bn with products coming off-patent with the current pipeline only replenishing $2.5bn in that time’.

Dr Walton continues, ‘It will be a major distraction to the merged entity and will mean that the merged company will potentially lose the opportunity to buy up biotechnology companies and their pipelines - leaving their competitors to do so. So, post merger, the rich pickings would have gone elsewhere’.

On the positive side, any potential merger would allow Pfizer to gain access to new therapies, for instance to vaccines, and to share in the remaining years of Enbrel, which is co-marketed with Amgen. Pfizer have complementary Central Nervous System (CNS) portfolios, and so the combined company will have a strong CNS presence. Dr Walton says, ‘As a combined company, there would be 20 products in Phase III, which sounds impressive, but they will need to rationalise to make the business work’.

PharmaDeals Review will be reporting on any potential monopoly issues, although the PharmaVentures’ business analysts say there is no obvious bar to any merger going ahead.

About PharmaVentures PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA, the Company works for a variety of clients from start-ups to global corporations. PharmaVentures publishes PharmaDeals Review (ISSN 1756-7874 online publication) providing expert opinion and analyses in the pharmaceutical and biotech field.

Contact Information
Fintan Walton, PhD
Mob Phone: +44 (0) 7887 548820

PharmaVentures
Magdalen Centre
Oxford Science Park
Oxford OX4 4GA, UK
Related article:
‘Wyeth Acquisition Could be Major Distraction for Pfizer’, PharmaDeals Review, Issue 103, published 23 January 2009.

Enquiries and a copy of the article is available from:
Lisa Holloway
Tel: +44 (0)1865 784 176

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1905804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
2. AUDIO from Medialink and Pfizer: Prescription for Safer Drugs Discussed in Washington
3. AUDIO from Medialink and Pfizer: A New Prescription for Safer Drugs
4. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
5. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
6. AUDIO From Medialink and Pfizer: Help Is Available for Caregivers and for Loved Ones
7. A Major Gift of Art and History: U-M Receives 45 Significant Medical Paintings From Pfizer
8. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
9. AUDIO from Medialink and Pfizer: Helping Uninsured Americans Achieve New Years Resolutions to be Healthier
10. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
11. AUDIO from Medialink and Pfizer: February is National Heart Month
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pfizer - Wyeth: Good Deal – Bad Deal?
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: